In Silico Bioinformatics Analysis on the Role of Long Non-Coding RNAs as Drivers and Gatekeepers of Androgen-Independent Prostate Cancer Using LNCaP and PC-3 Cells.

TERC TGF-β signaling bioinformatics biomarker ceRNA lncRNA miRNA prostate cancer

Journal

Current issues in molecular biology
ISSN: 1467-3045
Titre abrégé: Curr Issues Mol Biol
Pays: Switzerland
ID NLM: 100931761

Informations de publication

Date de publication:
01 Sep 2023
Historique:
received: 02 08 2023
revised: 19 08 2023
accepted: 28 08 2023
medline: 27 9 2023
pubmed: 27 9 2023
entrez: 27 9 2023
Statut: epublish

Résumé

Prostate cancer (PCa) is the leading cancer in men globally. The association between PCa and long non-coding RNAs (lncRNAs) has been reported. Aberrantly expressed lncRNAs have been documented in each of the cancer "hallmarks". Androgen signaling plays an important role in PCa progression. This study aimed to profile the aberrantly expressed lncRNAs in androgen-dependent (LNCaP) PCa compared to androgen-independent (PC-3) PCa cells. This was achieved by using a 384-well plate of PCa lncRNA gene panel. Differential expression of ±2 up or downregulation was determined using the CFX Maestro software v2.1. LncSEA and DIANA-miRPath were used to identify the enriched pathways. Telomerase RNA component (TERC) lncRNA was illustrated to participate in various tumourigenic classes by in silico bioinformatics analysis and was thus selected for validation using RT-qPCR. Further bioinformatics analysis revealed the involvement of differentially expressed lncRNAs in oncogenic pathways. Some lncRNAs undergo hypermethylation, others are encapsulated by exosomes, while others interact with several microRNAs (miRNAs), favouring tumourigenic pathways. Notably, TERC lncRNA was shown to interact with tumour-suppressor miRNAs hsa-miR-4429 and hsa-miR-320b. This interaction in turn activates TGF-β-signaling and ECM-receptor interaction pathways, favouring the progression of PCa. Understanding lncRNAs as competitive endogenous RNA molecules and their interactions with miRNAs may aid in the identification of novel prognostic PCa biomarkers and therapeutic targets.

Identifiants

pubmed: 37754243
pii: cimb45090459
doi: 10.3390/cimb45090459
pmc: PMC10528188
doi:

Types de publication

Journal Article

Langues

eng

Pagination

7257-7274

Subventions

Organisme : NRF
ID : 138139
Organisme : South African Medical Research Council
ID : 23108
Organisme : University of Pretoria
ID : 111

Références

Int J Mol Sci. 2021 Feb 23;22(4):
pubmed: 33672425
Nucleic Acids Res. 2018 Jan 4;46(D1):D239-D245
pubmed: 29156006
Cell Rep. 2015 Oct 6;13(1):209-221
pubmed: 26411689
Oncol Rep. 2017 Aug;38(2):959-966
pubmed: 28656255
Prostate. 2011 Nov;71(15):1668-79
pubmed: 21432867
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Oncol Lett. 2020 Jan;19(1):595-605
pubmed: 31897175
Mol Cancer. 2014 Jun 23;13:156
pubmed: 24953832
Mol Cancer Res. 2015 May;13(5):828-38
pubmed: 25700553
Nucleic Acids Res. 2015 Jul 1;43(W1):W460-6
pubmed: 25977294
BMC Urol. 2021 Mar 19;21(1):40
pubmed: 33740948
Cancer Sci. 2008 Jun;99(6):1092-9
pubmed: 18482052
Mol Cancer. 2017 Nov 9;16(1):169
pubmed: 29121972
Biochim Biophys Acta. 2016 Jan;1859(1):3-15
pubmed: 26477492
Eur Rev Med Pharmacol Sci. 2019 May;23(9):3760-3770
pubmed: 31115002
J Cell Physiol. 2020 Jan;235(1):185-193
pubmed: 31190335
Cancer Metastasis Rev. 2012 Jun;31(1-2):1-19
pubmed: 22138778
Oncol Rep. 2017 May;37(5):2964-2970
pubmed: 28405679
Front Oncol. 2022 Dec 14;12:1014949
pubmed: 36591473
Biomedicines. 2021 May 23;9(6):
pubmed: 34071109
Am J Cancer Res. 2018 Dec 01;8(12):2564-2574
pubmed: 30662812
Nature. 2013 Aug 29;500(7464):598-602
pubmed: 23945587
Mol Med. 2021 May 26;27(1):51
pubmed: 34039257
Oncotarget. 2017 Dec 30;9(12):10402-10416
pubmed: 29535815
Aging (Albany NY). 2019 Mar 5;11(5):1456-1470
pubmed: 30837348
BMC Mol Cell Biol. 2022 Nov 28;23(1):51
pubmed: 36443669
Bioengineered. 2022 Mar;13(3):6567-6578
pubmed: 35227173
Onco Targets Ther. 2020 Sep 24;13:9513-9523
pubmed: 33061435
J Pathol. 2018 Jan;244(1):11-24
pubmed: 28888037
J Mol Endocrinol. 2015 Feb;54(1):R15-29
pubmed: 25351819
Front Oncol. 2021 Jul 22;11:679244
pubmed: 34367966
Nucleic Acids Res. 2012 Aug;40(15):e115
pubmed: 22730293
DNA Cell Biol. 2021 Oct;40(10):1290-1297
pubmed: 34591651
Epigenetics. 2019 Dec;14(12):1141-1163
pubmed: 31284823
Biosci Rep. 2020 Jun 26;40(6):
pubmed: 32426838
Drug Discov Today. 2017 Feb;22(2):249-269
pubmed: 27890821
Cells. 2022 Sep 17;11(18):
pubmed: 36139487
Int J Oncol. 2019 Jan;54(1):77-86
pubmed: 30431069
Cell Mol Biol Lett. 2022 Feb 22;27(1):17
pubmed: 35193488
Ann Transl Med. 2022 Sep;10(18):963
pubmed: 36267723
Cancer Lett. 2021 Apr 28;504:15-22
pubmed: 33556545
RNA. 2007 Mar;13(3):313-6
pubmed: 17237358
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Science. 2019 Dec 20;366(6472):
pubmed: 31806698
Mol Cancer. 2017 Jun 21;16(1):107
pubmed: 28637507
Onco Targets Ther. 2020 Sep 18;13:9269-9280
pubmed: 32982313
Cancer Res. 2015 Sep 15;75(18):3728-37
pubmed: 26208906
Biosci Rep. 2018 Oct 2;38(5):
pubmed: 29967294
Cell Death Dis. 2019 Dec 12;10(12):950
pubmed: 31831728
Nucleic Acids Res. 2021 Jan 8;49(D1):D969-D980
pubmed: 33045741
BMC Genomics. 2019 Jun 3;20(1):454
pubmed: 31159744
FEBS Lett. 2006 Apr 17;580(9):2294-300
pubmed: 16580667
Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12216-21
pubmed: 11050243
Prostate. 2009 Jul 1;69(10):1077-90
pubmed: 19343732
Clin Exp Pharmacol Physiol. 2020 Nov;47(11):1783-1790
pubmed: 32621522
Noncoding RNA. 2021 Jun 08;7(2):
pubmed: 34201302

Auteurs

Mandisa Mbeje (M)

SAMRC Precision Oncology Research Unit (PORU), DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP), Pan African Cancer Research Institute (PACRI), University of Pretoria, Hatfield 0028, South Africa.
Department of Medical Oncology, Faculty of Health Sciences, Steve Biko Academic Hospital, University of Pretoria, Hatfield 0028, South Africa.

Jeyalakshmi Kandhavelu (J)

Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA.

Clement Penny (C)

Department of Internal Medicine, Faculty of Health Sciences, School of Clinical Medicine, University of the Witwatersrand, Parktown 2193, South Africa.

Mmamoletla Kgoebane-Maseko (M)

SAMRC Precision Oncology Research Unit (PORU), DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP), Pan African Cancer Research Institute (PACRI), University of Pretoria, Hatfield 0028, South Africa.
Department of Anatomical Pathology, Faculty of Health Sciences, University of Pretoria, Hatfield 0028, South Africa.

Zodwa Dlamini (Z)

SAMRC Precision Oncology Research Unit (PORU), DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP), Pan African Cancer Research Institute (PACRI), University of Pretoria, Hatfield 0028, South Africa.

Rahaba Marima (R)

SAMRC Precision Oncology Research Unit (PORU), DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP), Pan African Cancer Research Institute (PACRI), University of Pretoria, Hatfield 0028, South Africa.

Classifications MeSH